SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

BioCentury Publications, Inc.

September 03, 2009 08:00 ET

Thomson Reuters and BioCentury Showcase NewsMakers in the Biotech Industry

40 Leading Companies Selected Based on Capital Attraction and Upcoming News Events

NEW YORK, NY--(Marketwire - September 3, 2009) - Thomson Reuters and BioCentury are pleased to announce the presenting companies in their 16th Annual NewsMakers in the Biotech Industry conference. The conference takes place on September 16th at New York City's Millennium Broadway Hotel and Conference Center. The event -- the longest running independent investment meeting dedicated to the biopharma space -- remains the one turf neutral conference that brings together the Wall Street financial community to kick off the fall investment season.

With biotech share prices rising and fresh money flowing into the sector, NewsMakers again is perfectly timed for the current market. The NewsMakers Class of 2009 has capital, milestones and partnering opportunities to underpin the advance into next year.

The 40 public presenting companies have raised $1.2 billion so far this year to advance programs in cancer, infectious diseases, metabolic and endocrine disorders, and neurological, ophthalmic and cardiopulmonary diseases. Collectively, they have 41 marketed products, 12 compounds under review -- including seven with near-term Prescription Drug User Fee Act (PDUFA) dates -- and more than 200 clinical trials underway, 34 of which are Phase III.

The NewsMakers in the Biotech Industry Class of 2009 is leading the current biotech run. In the first eight months of the year, the group is up 79%, which compares to a 12% gain in the BioCentury 100, an 11% gain in the NASDAQ Biotechnology Index (NBI) and a 4% gain in the NYSE Arca Pharmaceutical Index (DRG).

More than 680 investment and pharmaceutical professionals have registered to attend. The money managers planning to attend the conference control more than $370 billion in equity assets, $52 billion in healthcare assets, and $17 billion in biotech assets. Online registration remains open through September 9th and attendance is complimentary for professional investment managers and pharmaceutical executives.

Register online today for NewsMakers2009!

"NewsMakers has consistently provided a unique forum in which some of industry's most compelling companies are able to relay their stories to an unparalleled cross-section of the sector's most experienced buyside and sellside professionals," said Adam Gurney, Founder of Kingsbridge Capital. "Kingsbridge proudly supports one of biotechnology's most important one day events of the year."

The 2009 Presenting Companies

This year's presenting companies were independently screened using Thomson Reuters and BioCentury's industry analysis and proprietary databases (listed on NASDAQ unless noted):

Alkermes Inc. (ALKS)
Avanir Pharmaceuticals Inc. (AVNR)
BioCryst Pharmaceuticals Inc. (BCRX)
BioDelivery Sciences International Inc. (BDSI)
BioSpecifics Technologies Corp. (BSTC)
Cadence Pharmaceuticals Inc. (CADX)
Cell Therapeutics Inc. (CTIC; Milan:CTIC)
Chelsea Therapeutics International Ltd. (CHTP)
Cleveland BioLabs Inc. (CBLI)
Cornerstone Therapeutics Inc. (CRTX)
Cytokinetics Inc. (CYTK)
Dendreon Corp. (DNDN)
Depomed Inc. (DEPO)
Dyax Corp. (DYAX)
Enzon Pharmaceuticals Inc. (ENZN)
Exelixis Inc. (EXEL)
Inspire Pharmaceuticals Inc. (ISPH)
Ista Pharmaceuticals Inc. (ISTA)
Jazz Pharmaceuticals Inc. (JAZZ)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Myriad Pharmaceuticals Inc. (MYRX)
Nektar Therapeutics (NKTR)
NeurogesX Inc. (NGSX)
OncoGenex Pharmaceuticals Inc. (OGXI)
Oncothyreon Inc. (ONTY; TSX:ONY)
Orexigen Therapeutics Inc. (OREX)
PDL BioPharma Inc. (PDLI)
Poniard Pharmaceuticals Inc. (PARD)
Progenics Pharmaceuticals Inc. (PGNX)
Protalix BioTherapeutics Inc. (NYSE-A: PLX)
Regeneron Pharmaceuticals Inc. (REGN)
Seattle Genetics Inc. (SGEN)
SuperGen Inc. (SUPG)
Transcept Pharmaceuticals Inc. (TSPT)
Vical Inc. (VICL)
ViroPharma Inc. (VPHM)
Vivus Inc. (VVUS)
Wilex AG (Xetra: WL6)
Xoma Ltd. (XOMA)

View the presenting company schedule and additional program highlights.

NewsMakers in the Biotech Industry continues to enjoy the support of leading investment and professional services firms. The sponsors for 2009 include Kingsbridge Capital; Ladenburg Thalmann & Co./Punk Ziegel Healthcare Group; Rodman & Renshaw; Thomson Reuters Healthcare and Science; WBB Securities; Wedbush Pacific Growth Life Sciences; and Yorkville Advisors.

About BioCentury

BioCentury Publications, Inc. provides essential biopharma industry intelligence from offices in the U.S. and Europe. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; the SciBX: Science-Business eXchange translational science joint publishing venture with Nature Publishing Group; and the BioCentury Extra online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence, an online business intelligence resource. For more information, visit www.biocentury.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people operating in over 100 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (NASDAQ: TRIN). For more information, go to www.thomsonreuters.com.

The Corporate Services business of Thomson Reuters provides more than 6,000 corporations worldwide with solutions across the Investor Relations, Corporate Communications, and Business Intelligence functions. Leveraging more than two decades of experience, the solutions are designed to increase the efficiency and effectiveness of business decision-making.

BioCentury™; The Bernstein Report on BioBusiness™ and BCIQ are trademarks of BioCentury Publications, Inc. SciBX and SciBX: Science-Business eXchange are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.

Contact Information